AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca is conducting a multicenter, non-interventional observational study titled ‘Multicenter, Non-interventional, Observational Study of Treatment and Biomarker Testing Patterns, Treatment Outcomes in Advanced/Metastatic NSCLC With and Without Actionable Genomic Alterations in Routine Clinical Practice in Russia.’ The study aims to evaluate treatment and biomarker testing patterns and outcomes in advanced/metastatic non-small cell lung cancer (NSCLC) patients in Russia, providing insights into real-world clinical practices.
This study does not involve any specific intervention or treatment, as it is observational in nature. Instead, it focuses on collecting data regarding existing treatment and biomarker testing practices in routine clinical settings.
The study is designed as an observational cohort with a prospective time perspective, meaning it will follow patients over time to observe outcomes. There is no allocation or masking involved, as the primary purpose is to gather data on current practices and outcomes.
The study began on March 20, 2024, with an estimated completion date yet to be announced. The most recent update was submitted on July 25, 2025, indicating ongoing data collection and analysis.
The results of this study could influence AstraZeneca’s stock performance by providing valuable insights into treatment patterns and outcomes in NSCLC, potentially impacting investor sentiment. Understanding these patterns is crucial for AstraZeneca and its competitors in the oncology market.
The study is ongoing, with further details available on the ClinicalTrials portal.